|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||36.26 - 41.97|
|52 Week Range||26.66 - 58.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.63|
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG) to form an Advisory Board to leverage the group’s expertise and further develop the company’s Parkinson’s disease (PD) program. In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis (P. gingivalis) in the development of Alzheimer’s disease at AD/PD™ 2021, the 15th International Conference on Alzheimer’s & Parkinson’s Diseases, which is being held virtually March 9-14, 2021.
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining ...
NEW YORK, NY / ACCESSWIRE / February 18, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cortexyme, Inc. ("Cortexyme" or "the Company") (NASDAQ:CRTX).